Search - tctmd.com

Displaying 361 - 380 of 528

Sort: Relevancy | Date

Presentation

Prasugrel vs Clopidogrel in STEMI Patients According to Timing of PCI

Presenter: J.A. Udell

June 17, 2014

News Daily News

Prasugrel Efficacy in STEMI Largely Unaffected by PCI Timing

Yael L. Maxwell

June 17, 2014

News Conference News EuroPCR 2014

PARIS Registry: Sex Disparity in DAPT Cessation Arises from Comorbidities

Yael L. Maxwell

May 21, 2014

News Daily News

Hospital-Acquired Thrombocytopenia Increases Risk of Hospital Bleeding, 1-Year Mortality

May 05, 2014

Presentation

Ticagrelor vs Clopidogrel in Patients with NSTE-ACS With or Without Revascularization

Presenter: D. Lindholm

April 25, 2014

News Daily News

PLATO Substudy: Ticagrelor Reduces Mortality in NSTE-ACS Patients Regardless of Revascularization

L.A. McKeown

April 25, 2014

News Daily News

Poor Adherence to Dabigatran Common, Linked with Worse Clinical Outcomes

Yael L. Maxwell

April 17, 2014

News Daily News

PLATO Analysis: No Sex-Based Difference in Ticagrelor’s Safety and Efficacy

April 16, 2014

Presentation

Impact of Early vs Late Clopidogrel Discontinuation on Stent Thrombosis Following PCI with First- and Second-Generation DES

Presenter: J.P. Loh

April 11, 2014

News Daily News

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

L.A. McKeown

April 11, 2014

News Daily News

El Antidiabético Aleglitazar No Logra Reducir los Resultados Isquémicos de Diabéticos con SCA de Reciente Aparición

L.A. McKeown

April 11, 2014

News Daily News

Diabetes Drug Aleglitazar Fails to Reduce Ischemic Outcomes in Diabetics with Recent ACS

L.A. McKeown

April 11, 2014

News Daily News

ARCTIC Analysis: Platelet Function Testing Does Not Enhance Secondary Prevention

Caitlin E. Cox

April 11, 2014

News Daily News

High Prasugrel Loading Dose Limits Platelet Reactivity after Primary PCI for STEMI

Caitlin E. Cox

April 09, 2014

Presentation

Incidence and Impact of Stent Thrombosis after PCI: Comparison of Cangrelor and Clopidogrel

Presenter: Philippe Généreux

April 02, 2014

News Conference News ACC 2014

CHAMPION PHOENIX Analysis: Cangrelor Reduces Early Stent Thrombosis, Suggesting Mortality Benefit

April 02, 2014

Presentation ACC 2014

Incidence and Impact of Stent Thrombosis During Percutaneous Coronary Intervention: Comparison of Cangrelor and Clopidogrel from the CHAMPION PHOENIX Trial

Presenter: Philippe Généreux

March 30, 2014

News Daily News

Mortality Benefit with ACE Inhibitors in Nonobstructive CAD

L.A. McKeown

March 20, 2014

News Daily News

Beneficio sobre la Mortalidad con Inhibidores de la ECA en la EAC No Obstructiva

L.A. McKeown

March 20, 2014

News Daily News

Un Panel de la FDA Rechaza el Cangrelor para las Indicaciones PCI y Terapia Puente

Yael L. Maxwell

February 13, 2014

Advertisement

Prasugrel vs Clopidogrel in STEMI Patients According to Timing of PCI

Prasugrel Efficacy in STEMI Largely Unaffected by PCI Timing

PARIS Registry: Sex Disparity in DAPT Cessation Arises from Comorbidities

Hospital-Acquired Thrombocytopenia Increases Risk of Hospital Bleeding, 1-Year Mortality

Ticagrelor vs Clopidogrel in Patients with NSTE-ACS With or Without Revascularization

PLATO Substudy: Ticagrelor Reduces Mortality in NSTE-ACS Patients Regardless of Revascularization

Poor Adherence to Dabigatran Common, Linked with Worse Clinical Outcomes

PLATO Analysis: No Sex-Based Difference in Ticagrelor’s Safety and Efficacy

Impact of Early vs Late Clopidogrel Discontinuation on Stent Thrombosis Following PCI with First- and Second-Generation DES

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

El Antidiabético Aleglitazar No Logra Reducir los Resultados Isquémicos de Diabéticos con SCA de Reciente Aparición

Diabetes Drug Aleglitazar Fails to Reduce Ischemic Outcomes in Diabetics with Recent ACS

ARCTIC Analysis: Platelet Function Testing Does Not Enhance Secondary Prevention

High Prasugrel Loading Dose Limits Platelet Reactivity after Primary PCI for STEMI

Incidence and Impact of Stent Thrombosis after PCI: Comparison of Cangrelor and Clopidogrel

CHAMPION PHOENIX Analysis: Cangrelor Reduces Early Stent Thrombosis, Suggesting Mortality Benefit

Incidence and Impact of Stent Thrombosis During Percutaneous Coronary Intervention: Comparison of Cangrelor and Clopidogrel from the CHAMPION PHOENIX Trial

Mortality Benefit with ACE Inhibitors in Nonobstructive CAD

Beneficio sobre la Mortalidad con Inhibidores de la ECA en la EAC No Obstructiva

Un Panel de la FDA Rechaza el Cangrelor para las Indicaciones PCI y Terapia Puente

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content